Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

32.34 +0.03 (+0.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunocore Holdings plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Immunocore Hldgs's Earnings Outlook
 
Via Benzinga
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
 
Via Benzinga
Where Immunocore Hldgs Stands With Analysts
 
Via Benzinga
Analyst Ratings for Immunocore Hldgs
 
Via Benzinga
Expert Ratings for Immunocore Hldgs
 
Via Benzinga
Recap: Immunocore Hldgs Q1 Earnings
 
Via Benzinga
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at the Bank of America Securities 2023 Health Care Conference
From Immunocore Holdings Limited
Via GlobeNewswire
Analyst Ratings for Immunocore Hldgs
 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Preview: Immunocore Holdings's Earnings
 
Via Benzinga
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
From Immunocore Holdings Limited
Via GlobeNewswire
Short Volatility Alert: Immunocore Hldgs
On Friday, shares of Immunocore Hldgs (NASDAQ: IMCR) experienced volatile short activity. After the activity, the stock price went up +3.38% to $54.81. The overall sentiment for IMCR has been Bearish. 
Via Benzinga
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
From Immunocore Holdings Limited
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
 
Via Benzinga
Immunocore Reveals First Data From HIV Infection Candidate Study
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Immunocore to present four posters at AACR Annual Meeting 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore Reports 2022 Financial Results and Provides Business Update
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023
From Immunocore Holdings Limited
Via GlobeNewswire
Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV
From Immunocore Holdings Limited
Via GlobeNewswire
Biotech's Drug Pipeline Expands From Melanoma To Other Cancers
Immunocore is the IBD Stock of the Day as the biotech company expands its pipeline. Earnings For IMCR stock are due in March. 
Via Investor's Business Daily
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
Immunocore to present at upcoming investor conferences
From Immunocore Holdings Limited
Via GlobeNewswire
3 Pharma Stocks That Will Mint Millionaires
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.